Amylyx Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary

• Amylyx Pharmaceuticals Inc AMLX.OQ reported a quarterly adjusted loss of 46 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -73 cents. The mean expectation of nine analysts for the quarter was for a loss of 45 cents per share. Wall Street expected results to range from -53 cents to -32 cents per share.

• Reported revenue was zero​; analysts expected zero.

• Amylyx Pharmaceuticals Inc's reported EPS for the quarter was a loss of 46 cents​.

• The company reported a quarterly loss of $41.44 million.

• Amylyx Pharmaceuticals Inc shares had risen by 27.8% this quarter and gained 116.7% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 0.5% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Amylyx Pharmaceuticals Inc is $10.00, about 18.1% above its last closing price of $8.19

This summary was machine generated from LSEG data August 7 at 05:59 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)